Over 900,000 Bottles of Heart Medication Recalled After Foreign Substance Found, FDA Confirms

The U.S. Food and Drug Administration (FDA) confirmed a recall of nearly 900,000 bottles of Lisinopril and Hydrochlorothiazide, a combination medication used to treat high blood pressure and heart failure, after detecting a foreign substance on tablets, according to a March 2024 alert. The recall affects specific lots of the drug produced by Teva Pharmaceuticals, a major generic drug manufacturer.

What Caused the Recall?

The FDA identified small, dark particles on the surface of the tablets during routine testing, according to a statement released on March 15, 2024. While the exact composition of the foreign substance has not been disclosed, the agency emphasized that it does not pose an immediate health risk to patients. However, the presence of such contaminants raises concerns about quality control in pharmaceutical manufacturing.

“The FDA takes any potential safety issue seriously and is working closely with the manufacturer to investigate the root cause,” said a spokesperson for the agency. “Patients are advised to consult their healthcare provider if they have questions about their medication.”

Which Products Are Affected?

The recall targets specific lots of Lisinopril/Hydrochlorothiazide 10 mg/25 mg and 20 mg/25 mg tablets. The affected batches include expiration dates ranging from April 2024 to December 2025, with batch numbers beginning with “4512” and “4513,” according to the FDA’s public database. The medication is distributed nationwide through retail pharmacies and wholesalers.

Patients can check if their medication is affected by visiting the FDA’s recall page or contacting their pharmacist. Teva Pharmaceuticals has also issued a press release urging customers to return the product to a pharmacy for a full refund.

How Are Patients Being Notified?

The FDA and Teva Pharmaceuticals have initiated direct notifications to healthcare providers and pharmacies, as required by regulatory guidelines. Patients may not receive individual alerts but are encouraged to check the recalled lots using the FDA’s online tool. The agency has also partnered with major pharmacy chains, including Walgreens and CVS, to display recall information at checkout counters.

“This is a precautionary measure to ensure patient safety,” said a Teva spokesperson. “We are committed to maintaining the highest standards of quality and are cooperating fully with the FDA’s investigation.”

What Should Patients Do?

Patients taking the affected medication are advised to continue their treatment unless instructed otherwise by a healthcare provider. The FDA has stated that the risk of harm from the foreign substance is low, but individuals experiencing unusual symptoms should seek medical attention. Those who wish to discontinue the medication should consult their doctor for alternative options.

“It’s important to remember that this recall is a rare occurrence and does not reflect the overall safety of the drug,” said Dr. Sarah Lin, a pharmacologist at the University of California, San Francisco. “Patients should not stop their medication without professional guidance.”

How Common Are Pharmaceutical Recalls?

Pharmaceutical recalls are relatively rare but not unheard of. In 2023, the FDA reported over 300 drug recalls, most of which were voluntary actions by manufacturers. Contamination issues, like the one in this case, account for a small percentage of recalls, with the majority related to labeling errors or potency concerns.

Historically, similar incidents have led to stricter oversight. For example, the 2018 recall of certain blood pressure medications due to a carcinogenic impurity prompted the FDA to expand its testing protocols. This latest recall may further accelerate efforts to enhance quality control measures across the industry.

What’s Next for the Manufacturer?

The FDA has launched an inspection of Teva’s manufacturing facility in Pennsylvania to determine how the contamination occurred. The agency has not yet specified whether the issue stems from raw material suppliers, production processes, or packaging. Teva has not commented on the findings of the investigation.

Regulatory experts suggest the company may face fines or mandatory reforms if the inspection reveals systemic quality control failures. “This could set a precedent for more rigorous audits of generic drug manufacturers,” said Michael Torres, a healthcare policy analyst at the Brookings Institution.